Digital pathology is used within pathology, computer science and image analysis and is transforming how pathologists diagnose and research diseases. Within this article, we will conduct a deep dive into the benefits of digital pathology. While doing this, we will emphasise its impact on healthcare outcomes, research and education.
Read article here:
https://sourcebioscience.com/what-are-the-benefits-of-digital-pathology/
Stevenage, UK, 22 October 2024 - Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces it is to present new data on its innovative gene-silencing platform at the European Society of Gene & Cell Therapy (ESGCT) Conference in Rome 22-25 October.
CPI has fully opened its RNA Centre of Excellence to support the rising demand for RNA-based therapies and vaccines. The service offers comprehensive support, including plasmid DNA production, RNA transcription, purification, and formulation, alongside process development, analytics, and regulatory guidance.
At Broken String Biosciences, we are driving innovation in genome editing technologies to enable safer, more effective cell and gene therapies. Our mission is to advance the next generation of precise, safe, and efficient therapies through our cutting-edge technology platforms.
Our flagship technology, INDUCE-seq™, offers rapid and accurate DNA break mapping, providing critical insights into how genome editors interact with DNA. This data-driven approach helps unlock new editing targets and supports the development of life-saving therapies that are safer by design.
About Us:
Domainex is a multi-award winning integrated drug discovery CRO that has been setting the highest standards in drug discovery, with a particular emphasis on small molecule research, since 2001. We work in partnership with clients from a variety of sectors including academic, pharmaceutical, biotechnology and patient foundation organisations around the world. Our vision is to be the pre-eminent partner for innovative drug discovery services that improve the quality of life for people living with disease.
Domainex is a multi-award winning integrated drug discovery CRO that has been setting the highest standards in drug discovery, with a particular emphasis on small molecule research, since 2001. We work in partnership with clients from a variety of sectors including academic, pharmaceutical, biotechnology and patient foundation organisations around the world. Our vision is to be the pre-eminent partner for innovative drug discovery services that improve the quality of life for people living with disease.
Featuring a diverse lineup of international speakers, thought leaders and business leaders from within and beyond the industry to bring in new perspectives and insights. A dynamic mix of talks, masterclasses, and panel discussions.
9am to 5pm
*One Nucleus Members from biotech/pharma, including CROs/CDMOs, receive 20% off registration - email info@onenucleus.com quoting 'BPLS24' for the discount code.
tranScrip is delighted to announce the appointment of Roz Sutton as Senior Director of Regulatory Affairs. Roz brings two decades of experience in Global Regulatory Affairs, having held leadership roles at top pharmaceutical companies including Roche and GSK, as well as in regulatory consultancy at DLRC. Her appointment underscores tranScrip’s commitment to strengthening its regulatory team as it continues to expand its expertise and service offerings.
We are delighted to announce that Dr. Kathryn (Kate) Owen has joined tranScrip as Executive Medical Director in our Early Development Group.
Kate brings with her 24 years of extensive experience as a consultant Pharmaceutical Physician, with a specialised focus in oncology and haemato-oncology. She has an exceptional track record in early clinical development, guiding projects from candidate drug selection through to phase IIb trials.